Jan 30, 2008 by Brian LawlerEli Lilly Is ResilientThe company is ready to handle competition from generics.
Jan 30, 2008 by Brian LawlerMore Breaks for BioMarinThere's encouraging news about an enzyme replacement drug.
Jan 30, 2008 by Brian LawlerThe Competition Bites TrimerisRivals lead to lower sales of the pharmaceutical's only marketed drug.
Jan 30, 2008 by Brian LawlerThe President's Stimulus Plan Misses the MarkThe current proposal would boost the wrong part of the economy.
Jan 29, 2008 by Brian LawlerBioSante's Gamble Against GenericsBioSante releases more info on the pivotal studies for its lead drug.
Jan 29, 2008 by Brian LawlerGenentech Adds to Avastin's ArsenalThe lead drug gains another use -- just not the one investors expected.
Jan 29, 2008 by Brian LawlerIcahn Tries to Board USS BiogenCarl Icahn attempts a board shakeup at Biogen.
Jan 28, 2008 by Brian LawlerA Great Way to Recession-Proof Your PortfolioIf you want a recession-resistant portfolio, invest in large-cap pharmaceuticals.
Jan 28, 2008 by Brian LawlerCan Encysive Catch the Competition?When will Encysive get FDA approval to enter the PAH market that's fattening up its competitors?
Jan 28, 2008 by Brian LawlerA Wing and a Prayer for AmgenAmgen announces data from its top pipeline drug candidate.
Jan 25, 2008 by Brian LawlerWhat's Not to Like About Gilead?Gilead announces its fourth-quarter financial results.
Jan 25, 2008 by Brian LawlerAmgen: Punched Out or Still Fighting?Amgen releases 2007 financial results and guidance for 2008.
Jan 24, 2008 by Brian LawlerPfiltering Through Pfizer's YearThe pharmaceutical firm releases fourth-quarter financials.
Jan 24, 2008 by Brian LawlerAdolor Advisory Panel AftermathAn FDA advisory panel votes favorably on Adolor's lead drug.
Jan 24, 2008 by Brian LawlerVertex Under the GunVertex announces development plans for its lead drug.
Jan 23, 2008 by Brian LawlerHot and Not at ExelixisOne of the drugmaker's candidates gets dumped, but another finds a buyer.
Jan 22, 2008 by Brian LawlerAdolor Under the FDA's SpotlightThe FDA releases its documents on Adolor's lead drug.
